WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.
Recent spread of avian influenza A (H5N1) virus to poultry and wild birds has increased the threat of human infections with H5N1 virus worldwide. Despite international agreement to stockpile antivirals, evidence-based guidelines for their use do not exist. WHO assembled an international multidiscipl...
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Fformat: | Journal article |
| Iaith: | English |
| Cyhoeddwyd: |
2007
|
| _version_ | 1826264588894601216 |
|---|---|
| author | Schünemann, H Hill, SR Kakad, M Bellamy, R Uyeki, T Hayden, F Yazdanpanah, Y Beigel, J Chotpitayasunondh, T Del Mar, C Farrar, J Tran, T Ozbay, B Sugaya, N Fukuda, K Shindo, N Stockman, L Vist, G Croisier, A Nagjdaliyev, A Roth, C Thomson, G Zucker, H Oxman, A |
| author_facet | Schünemann, H Hill, SR Kakad, M Bellamy, R Uyeki, T Hayden, F Yazdanpanah, Y Beigel, J Chotpitayasunondh, T Del Mar, C Farrar, J Tran, T Ozbay, B Sugaya, N Fukuda, K Shindo, N Stockman, L Vist, G Croisier, A Nagjdaliyev, A Roth, C Thomson, G Zucker, H Oxman, A |
| author_sort | Schünemann, H |
| collection | OXFORD |
| description | Recent spread of avian influenza A (H5N1) virus to poultry and wild birds has increased the threat of human infections with H5N1 virus worldwide. Despite international agreement to stockpile antivirals, evidence-based guidelines for their use do not exist. WHO assembled an international multidisciplinary panel to develop rapid advice for the pharmacological management of human H5N1 virus infection in the current pandemic alert period. A transparent methodological guideline process on the basis of the Grading Recommendations, Assessment, Development and Evaluation (GRADE) approach was used to develop evidence-based guidelines. Our development of specific recommendations for treatment and chemoprophylaxis of sporadic H5N1 infection resulted from the benefits, harms, burden, and cost of interventions in several patient and exposure groups. Overall, the quality of the underlying evidence for all recommendations was rated as very low because it was based on small case series of H5N1 patients, on extrapolation from preclinical studies, and high quality studies of seasonal influenza. A strong recommendation to treat H5N1 patients with oseltamivir was made in part because of the severity of the disease. Similarly, strong recommendations were made to use neuraminidase inhibitors as chemoprophylaxis in high-risk exposure populations. Emergence of other novel influenza A viral subtypes with pandemic potential, or changes in the pathogenicity of H5N1 virus strains, will require an update of these guidelines and WHO will be monitoring this closely. |
| first_indexed | 2024-03-06T20:10:15Z |
| format | Journal article |
| id | oxford-uuid:2a4f637e-b341-4ad2-b010-2a075e23fef1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:10:15Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:2a4f637e-b341-4ad2-b010-2a075e23fef12022-03-26T12:24:23ZWHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2a4f637e-b341-4ad2-b010-2a075e23fef1EnglishSymplectic Elements at Oxford2007Schünemann, HHill, SRKakad, MBellamy, RUyeki, THayden, FYazdanpanah, YBeigel, JChotpitayasunondh, TDel Mar, CFarrar, JTran, TOzbay, BSugaya, NFukuda, KShindo, NStockman, LVist, GCroisier, ANagjdaliyev, ARoth, CThomson, GZucker, HOxman, ARecent spread of avian influenza A (H5N1) virus to poultry and wild birds has increased the threat of human infections with H5N1 virus worldwide. Despite international agreement to stockpile antivirals, evidence-based guidelines for their use do not exist. WHO assembled an international multidisciplinary panel to develop rapid advice for the pharmacological management of human H5N1 virus infection in the current pandemic alert period. A transparent methodological guideline process on the basis of the Grading Recommendations, Assessment, Development and Evaluation (GRADE) approach was used to develop evidence-based guidelines. Our development of specific recommendations for treatment and chemoprophylaxis of sporadic H5N1 infection resulted from the benefits, harms, burden, and cost of interventions in several patient and exposure groups. Overall, the quality of the underlying evidence for all recommendations was rated as very low because it was based on small case series of H5N1 patients, on extrapolation from preclinical studies, and high quality studies of seasonal influenza. A strong recommendation to treat H5N1 patients with oseltamivir was made in part because of the severity of the disease. Similarly, strong recommendations were made to use neuraminidase inhibitors as chemoprophylaxis in high-risk exposure populations. Emergence of other novel influenza A viral subtypes with pandemic potential, or changes in the pathogenicity of H5N1 virus strains, will require an update of these guidelines and WHO will be monitoring this closely. |
| spellingShingle | Schünemann, H Hill, SR Kakad, M Bellamy, R Uyeki, T Hayden, F Yazdanpanah, Y Beigel, J Chotpitayasunondh, T Del Mar, C Farrar, J Tran, T Ozbay, B Sugaya, N Fukuda, K Shindo, N Stockman, L Vist, G Croisier, A Nagjdaliyev, A Roth, C Thomson, G Zucker, H Oxman, A WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. |
| title | WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. |
| title_full | WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. |
| title_fullStr | WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. |
| title_full_unstemmed | WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. |
| title_short | WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. |
| title_sort | who rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza a h5n1 virus |
| work_keys_str_mv | AT schunemannh whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT hillsr whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT kakadm whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT bellamyr whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT uyekit whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT haydenf whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT yazdanpanahy whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT beigelj whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT chotpitayasunondht whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT delmarc whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT farrarj whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT trant whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT ozbayb whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT sugayan whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT fukudak whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT shindon whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT stockmanl whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT vistg whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT croisiera whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT nagjdaliyeva whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT rothc whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT thomsong whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT zuckerh whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus AT oxmana whorapidadviceguidelinesforpharmacologicalmanagementofsporadichumaninfectionwithavianinfluenzaah5n1virus |